Anders Nykjaer
Founder at Insusense ApS
Profile
Anders Nykjaer is the founder of Recepticon ApS, which was founded in 2001.
He held the title of Co-Chief Scientific Officer from 2009 to 2010.
Dr. Nykjaer is also the founder of Insusense ApS.
Currently, he is a Professor at the University of Aarhus.
In the past, he worked as Co-Chairman at Lundbeck Foundation.
Dr. Nykjaer received his doctorate degrees from the University of Aarhus in 1991 and 1995.
Anders Nykjaer active positions
| Companies | Position | Start |
|---|---|---|
| University of Aarhus | Corporate Officer/Principal | - |
Insusense ApS
 Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Founder | - |
Former positions of Anders Nykjaer
| Companies | Position | End |
|---|---|---|
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Founder | 2010-03-22 |
Lundbeck Foundation
 Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Chairman | - |
Training of Anders Nykjaer
| University of Aarhus | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Health Technology |
Lundbeck Foundation
Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Miscellaneous |
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- Anders Nykjaer